The companies will co-develop an over-the-counter product using DERM's TopiCare polymer delivery compounds with an undisclosed SmithKline Beecham formulation. SmithKline will have the exclusive option to market the product worldwide and will be liable for...

DERM began U.S. sales of its Avita cream, a topical form of retinoic acid to treat acne. Product stocking to wholesalers will be completed by the third quarter. DERM's contract sales force will market the...

DERM received U.K. marketing approval for Avita, retinoic acid cream and gel formulations used to treat acne. The U.K. will serve as a sponsor to help DERM gain approval in other European countries. DERM plans...

Penederm Inc. (DERM), Foster City, Calif.   Business: Dermatology, Drug delivery   Appointed: Director David Collins, to chairman  ...

The FDA approved Mentax , DERM's 1 percent butenafine HC1 cream, to treat tinea corporis (ringworm) and tinea cruris (groin fungus). The agency approved the product in October 1996 to treat interdigital tinea pedis (athlete's foot)....

Mylan completed its acquisition of DERM (see BioCentury, June 29). Penederm Inc. (DERM), Foster City, Calif.   Mylan Laboratories Inc., Pittsburgh, Penn.   Business: Dermatology, Drug delivery  ...

The companies will co-promote DERM's Mentax topical antifungal product to podiatrists in the U.S. Penederm Inc. (DERM), Foster City, Calif.   Pedinol Pharmacal Inc., Pharmingdale, N.Y.   Business: Dermatology  ...

MYL's Bertek Pharmaceuticals Inc. subsidiary (Sugar Land, Texas) will co-promote DERM's Avita, a topical retinoic acid product to treat acne. The agreement provides an upfront license fee and prepaid co-promotion payments to DERM totaling from...

Mylan, a developer of generic pharmaceuticals delivered orally and via transdermal patches, will acquire DERM in a stock deal worth $205 million based on Mylan's closing price prior to the announcement. Mylan will issue 0.68...

With the exception of Baxter International Inc. 's purchase of Somatogen Inc. in February, pharmaceutical company acquisitions of product-oriented biotechs this year have been limited mostly to those biotech companies with products on the market....